^
Association details:
Biomarker:EML4-ALK variant 2
Cancer:Lung Adenocarcinoma
Drug Class:ALK inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

Long-term treatment with ALK inhibitors for postoperative recurrence of ALK-rearranged lung cancer

Published date:
06/15/2022
Excerpt:
We encountered a 40-year-old female patient...Echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) fusion gene, variant 2 was identified in her cancer cells….By changing the ALK inhibitors from the 1st to 3rd generation each time when metastases were identified and incorporating local treatments in a timely fashion, such as metastasectomy or radiation therapy, she has survived for more than 11 years since the start of treatment...
DOI:
https://doi.org/10.1007/s13691-022-00557-8